0000000001307752

AUTHOR

Stefanie Meckes-ferber

showing 2 related works from this author

Gender-, age- and time-dependent dosing of growth hormone in adults - real-world data from a decade of clinical practice in Germany.

2017

We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003-2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…

AdultMalemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiology030209 endocrinology & metabolismGrowth hormoneGrowth hormone deficiency03 medical and health sciencesInsulin-like growth factor0302 clinical medicineEndocrinologySex FactorsInternal medicineGermanymedicineHumansDosingDwarfism PituitaryAgedDose-Response Relationship Drugbusiness.industryHuman Growth HormoneAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseClinical PracticeEndocrinologyTreatment OutcomeTransgender hormone therapy030220 oncology & carcinogenesisGh treatmentFemalebusinessReal world dataGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Gender-, age- and time-dependent dosing of growth hormone in adults – real-world data from a decade of clinical practice in Germany

2017

We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003–2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…

researchProduct